Puration Begins To Outgrow Production Capacity And Plans Bottling Plant Expansion

GlobeNewswire - finance.yahoo.com Posted 5 years ago

DALLAS, March 12, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (PURA) (“PURA”) today announced that the expanding demand for its EVERx CBD Sports Water is pushing the limits of its current bottling production capacity. “Having our orders for EVERx CBD Sports Water begin to overwhelm our bottling production capacity is an exciting problem,” said Brian Shibley, CEO of Puration. “While we are delighted to have great demand for EVERx, the risk of getting behind on production is nonetheless still a problem, no matter how exciting.  We have some online customers already frustrated with slow delivery and that’s not good.  We certainly don’t want to get behind with our wholesale buyers and we need to go above and beyond to make it up to our online buyers.”  PURA recently announced beginning discussions with its current bottler about the possibility of PURA acquiring the bottler.  The proposal to acquire the current bottler includes investment plans to expand the current bottler’s production capacity.  “As we continue to innovate new beverages, a key bottling partner or in-house capacity its essential,” explained Mr. Shibley.  PURA is also exploring independent bottling capacity acquisitions in addition to considering building out an all new plant.  Management anticipates finalizing expansion plans by the end of this month. “Be it an acquisition or a new build out, the plan will be finalized this month and we will proceed quickly to expand production capacity one way or another.”

Analyst Speculative Buy Recommendation and $0.25 PPS Target with $0.35 Upside

Goldman Small Cap Research issued a research update on Puration, Inc. (PURA) last week recommending a 'speculative-buy' rating with a target price-per-share of $0.25, with noted potential upside to the $0.35 mark. 

For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Contact:
Puration, Inc.
Brian Shibley,
[email protected]
(800) 861-1350